Industry News

• A. Bruce Montgomery, M.D., joins ZymoGenetics board of directors  ZymoGenetics announced that A. Bruce Montgomery, M.D., was named to the company's Board of Directors. Dr. Montgomery serves as Senior Vice President and Head of Respiratory Therapeutics at Gilead Sciences, and previously founded Corus Pharma.
  ZymoGenetics, Inc. March 11, 2010  
• Seattle Genetics expands antibody-drug conjugate patent Portfolio  Seattle Genetics announced that the U.S. PTO has issued a patent related to its antibody-drug conjugate ADC technology. U.S. Patent No. 7,659,241 covers cleavable linkers and potent auristatin drug payloads used in certain of Seattle Genetics' ADC programs, most notably brentuximab vedotin.
  Seattle Genetics, Inc. March 11, 2010  
• Scientists discover causative genetic mutation associated with neurologic disorder  Scientists using advanced genomic analysis technologies from Life Technologies have sequenced an individual's genome and identified the specific causative mutation associated with Charcot-Marie-Tooth Disease (CMT).
  Life Technologies Corporation March 10, 2010  
• CombiMatrix Corporation reports fourth quarter 2009 financial results  Revenues for the fourth quarter of 2009 were $1.1 million versus $970,000 for the third quarter of 2009 and $1.2 million in the fourth quarter of 2008.
  CombiMatrix Corporation March 10, 2010  
• Monsanto ranks no. 28 on the 2010 DiversityInc Top 50 Companies for Diversity(R) list  Monsanto Company has been named to The 2010 DiversityInc Top 50 Companies for Diversity(R) list for its demonstrated use of measurable diversity best practices and results. A total of 449 companies participated this year, up 12 percent from last year.
  Monsanto Company March 10, 2010  
• Vermillion announces Scientific Advisory Board appointments  Vermillion announced the appointment of its distinguished Scientific Advisory Board to assist in directing the Company's product development strategies.
  Vermillion, Inc. March 10, 2010  
• Affymax(R) receives $5 million milestone payment on initiation of Phase 3 clinical trials  Affymax announced that it has received a $5 million development milestone payment from Takeda Pharmaceutical as part of the companies' exclusive global agreement to develop and commercialize Hematide(TM), Affymax's investigational drug for the treatment of anemia in chronic renal failure patients.
  Affymax, Inc. March 10, 2010  
• Cytokinetics announces Orphan Drug Designation granted to CK-2017357  Cytokinetics announced that its fast skeletal muscle troponin activator, CK-2017357, has been granted orphan-drug designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of amyotrophic lateral sclerosis (ALS), also commonly known as Lou Gehrig's Disease.
  Cytokinetics, Incorporated March 10, 2010  
• QLT announces fourth quarter and year end 2009 results  QLT sold its subsidiary, QLT USA, including its Eligard(R) line of products, on October 1, 2009. The Company was paid $20 million on closing, and will receive $10 million on October 1, 2010 and up to an additional $200 million in quarterly payments.
  QLT, Inc. March 10, 2010  
• QLT announces Phase II clinical trial results and development plans  QLT announced results from Phase II clinical trials and a device study for the punctal plug delivery system (PPDS). These studies are part of a development program that is being conducted by QLT's wholly-owned subsidiary, QLT Plug Delivery.
  QLT, Inc. March 10, 2010  

   (next 10 articles)